Diffuse large B-cell lymphoma successfully treated with amplified natural killer therapy alone: A case report

BACKGROUND: The prognosis of patients with advanced diffuse large B-cell lymphoma (DLBCL) is poor, with a 5-year survival rate of approximately 50%. The mainstay of treatment is multidrug combination chemotherapy, which has been associated with serious side effects. Amplified natural killer (ANK) ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Kenjiro, Nagai, Syo, Okubo, Yuji, Teshigawara, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643074/
https://www.ncbi.nlm.nih.gov/pubmed/37969464
http://dx.doi.org/10.12998/wjcc.v11.i30.7432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643074/
https://www.ncbi.nlm.nih.gov/pubmed/37969464
http://dx.doi.org/10.12998/wjcc.v11.i30.7432

Ejemplares similares